Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVDD combination therapy for newly diagnosed multiple myeloma
NCT00724568Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 month. Started May 2008; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00724568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00724568.